143 related articles for article (PubMed ID: 30515751)
1. Radioimmunotherapy (RIT) for Follicular Lymphoma achieves long term lymphoma control in first line and at relapse: 8-year follow-up data of 281 patients from the international RIT-registry.
Hohloch K; Windemuth-Kieselbach C; Kolz J; Zinzani PL; Cacchione R; Jurczak W; Bischof Delaloye A; Trümper L; Scholz CW
Br J Haematol; 2019 Mar; 184(6):949-956. PubMed ID: 30515751
[TBL] [Abstract][Full Text] [Related]
2. Yttrium-90-Ibritumomab Tiuxetan (Zevalin®) Radioimmunotherapy after Cytoreduction with ESHAP Chemotherapy in Patients with Relapsed Follicular Non-Hodgkin Lymphoma: Final Results of a Phase II Study.
Puvvada SD; Guillén-Rodríguez JM; Yan J; Inclán L; Heard K; Rivera XI; Anwer F; Mahadevan D; Schatz JH; Persky DO
Oncology; 2018; 94(5):274-280. PubMed ID: 29471300
[TBL] [Abstract][Full Text] [Related]
3. Radioimmunotherapy for mantle cell lymphoma: 5-year follow-up of 90 patients from the international RIT registry.
Hohloch K; Windemuth-Kieselbach C; Zinzani PL; Cacchione R; Jurczak W; Suh C; Trümper L; Scholz CW
Ann Hematol; 2020 May; 99(5):1073-1079. PubMed ID: 32125469
[TBL] [Abstract][Full Text] [Related]
4. Radioimmunotherapy for first-line and relapse treatment of aggressive B-cell non-Hodgkin lymphoma: an analysis of 215 patients registered in the international RIT-Network.
Hohloch K; Lankeit HK; Zinzani PL; Scholz CW; Lorsbach M; Windemuth-Kieselbach C; Trümper L
Eur J Nucl Med Mol Imaging; 2014 Aug; 41(8):1585-92. PubMed ID: 24722703
[TBL] [Abstract][Full Text] [Related]
5. High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis.
Gopal AK; Gooley TA; Maloney DG; Petersdorf SH; Eary JF; Rajendran JG; Bush SA; Durack LD; Golden J; Martin PJ; Matthews DC; Appelbaum FR; Bernstein ID; Press OW
Blood; 2003 Oct; 102(7):2351-7. PubMed ID: 12750161
[TBL] [Abstract][Full Text] [Related]
6. FDG-PET in the assessment of patients with follicular lymphoma treated by ibritumomab tiuxetan Y 90: multicentric study.
Lopci E; Santi I; Derenzini E; Fonti C; Savelli G; Bertagna F; Bellò M; Botto B; Huglo D; Morschhauser F; Zinzani P; Fanti S
Ann Oncol; 2010 Sep; 21(9):1877-1883. PubMed ID: 20147744
[TBL] [Abstract][Full Text] [Related]
7. Oncological outcome and recurrence pattern analysis after involved-field irradiation in combination with rituximab for early-stage nodal and extranodal follicular lymphoma.
König L; Herfarth K; Hörner-Rieber J; Dietrich S; Wiegel T; Debus J; Viardot A
Strahlenther Onkol; 2020 Aug; 196(8):705-714. PubMed ID: 32377821
[TBL] [Abstract][Full Text] [Related]
8. Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma.
Leonard JP; Coleman M; Kostakoglu L; Chadburn A; Cesarman E; Furman RR; Schuster MW; Niesvizky R; Muss D; Fiore J; Kroll S; Tidmarsh G; Vallabhajosula S; Goldsmith SJ
J Clin Oncol; 2005 Aug; 23(24):5696-704. PubMed ID: 16110029
[TBL] [Abstract][Full Text] [Related]
9. (90)Yttrium-ibritumomab-tiuxetan as first-line treatment for follicular lymphoma: 30 months of follow-up data from an international multicenter phase II clinical trial.
Scholz CW; Pinto A; Linkesch W; Lindén O; Viardot A; Keller U; Hess G; Lastoria S; Lerch K; Frigeri F; Arcamone M; Stroux A; Frericks B; Pott C; Pezzutto A
J Clin Oncol; 2013 Jan; 31(3):308-13. PubMed ID: 23233718
[TBL] [Abstract][Full Text] [Related]
10. Long term efficacy and safety of Fludarabine, Cyclophosphamide and Rituximab regimen followed by (90)Y-ibritumomab tiuxetan consolidation for the treatment of relapsed grades 1 and 2 follicular lymphoma.
Pisani F; Sciuto R; Dessanti ML; Giannarelli D; Kayal R; Rea S; Marchesi F; Marino M
Exp Hematol Oncol; 2015; 4():17. PubMed ID: 26120498
[TBL] [Abstract][Full Text] [Related]
11. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma.
Morschhauser F; Radford J; Van Hoof A; Vitolo U; Soubeyran P; Tilly H; Huijgens PC; Kolstad A; d'Amore F; Gonzalez Diaz M; Petrini M; Sebban C; Zinzani PL; van Oers MH; van Putten W; Bischof-Delaloye A; Rohatiner A; Salles G; Kuhlmann J; Hagenbeek A
J Clin Oncol; 2008 Nov; 26(32):5156-64. PubMed ID: 18854568
[TBL] [Abstract][Full Text] [Related]
12. 90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the International, Randomized, Phase III First-LineIndolent trial.
Morschhauser F; Radford J; Van Hoof A; Botto B; Rohatiner AZ; Salles G; Soubeyran P; Tilly H; Bischof-Delaloye A; van Putten WL; Kylstra JW; Hagenbeek A
J Clin Oncol; 2013 Jun; 31(16):1977-83. PubMed ID: 23547079
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of radioimmunotherapy (RIT) in treatment of non-Hodgkin's lymphoma in the community setting.
Hadid T; Raufi A; Kafri Z; Mandziara M; Kalabat J; Szpunar S; Kolizeras K; Steigelman M; Al-Katib A
Nucl Med Biol; 2016 Apr; 43(4):227-31. PubMed ID: 27067042
[TBL] [Abstract][Full Text] [Related]
14. Radioimmunotherapy confers long-term survival to lymphoma patients with acceptable toxicity: registry analysis by the International Radioimmunotherapy Network.
Hohloch K; Delaloye AB; Windemuth-Kieselbach C; Gómez-Codina J; Linkesch W; Jurczak W; Cacchione R; Suh C; Zinzani PL; Trümper L
J Nucl Med; 2011 Sep; 52(9):1354-60. PubMed ID: 21828114
[TBL] [Abstract][Full Text] [Related]
15. Follicular lymphoma at relapse after rituximab containing regimens: comparison of time to event intervals prior to and after 90 Y-ibritumomab-tiuxetan.
Cicone F; Russo E; Carpaneto A; Prior JO; Delaloye AB; Scopinaro F; Ketterer N
Hematol Oncol; 2011 Sep; 29(3):131-8. PubMed ID: 20862654
[TBL] [Abstract][Full Text] [Related]
16. 90-yttrium-ibritumomab tiuxetan as first-line treatment for follicular lymphoma: updated efficacy and safety results at an extended median follow-up of 9.6 years.
Rieger K; De Filippi R; Lindén O; Viardot A; Hess G; Lerch K; Neumeister P; Stroux A; Peuker CA; Pezzutto A; Pinto A; Keller U; Scholz CW
Ann Hematol; 2022 Apr; 101(4):781-788. PubMed ID: 35150296
[TBL] [Abstract][Full Text] [Related]
17. Comparing the cost-effectiveness of rituximab maintenance and radioimmunotherapy consolidation versus observation following first-line therapy in patients with follicular lymphoma.
Chen Q; Ayer T; Nastoupil LJ; Rose AC; Flowers CR
Value Health; 2015 Mar; 18(2):189-97. PubMed ID: 25773554
[TBL] [Abstract][Full Text] [Related]
18. Addition of Rituximab to Involved-Field Radiation Therapy Prolongs Progression-free Survival in Stage I-II Follicular Lymphoma: Results of a Multicenter Study.
Ruella M; Filippi AR; Bruna R; Di Russo A; Magni M; Caracciolo D; Passera R; Matteucci P; Di Nicola M; Corradini P; Parvis G; Gini G; Olivieri A; Ladetto M; Ricardi U; Tarella C; Devizzi L
Int J Radiat Oncol Biol Phys; 2016 Mar; 94(4):783-91. PubMed ID: 26972651
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of (90) yttrium-ibritumomab-tiuxetan for untreated follicular lymphoma patients. An Italian cooperative study.
Ibatici A; Pica GM; Nati S; Vitolo U; Botto B; Ciochetto C; Petrini M; Galimberti S; Ciabatti E; Orciuolo E; Zinzani PL; Cascavilla N; Guolo F; Fraternali Orcioni G; Carella AM
Br J Haematol; 2014 Mar; 164(5):710-6. PubMed ID: 24344981
[TBL] [Abstract][Full Text] [Related]
20. A systematic literature review and meta-analysis of radioimmunotherapy consolidation for patients with untreated follicular lymphoma.
Rose AC; Shenoy PJ; Garrett G; Seward M; Kucuk RA; Doksansky H; Nastoupil LJ; Flowers CR
Clin Lymphoma Myeloma Leuk; 2012 Dec; 12(6):393-9. PubMed ID: 23158095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
